Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Recursion Pharmaceuticals Inc Cl A (RXRX)
Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,646,335
  • Shares Outstanding, K 216,623
  • Annual Sales, $ 39,840 K
  • Annual Income, $ -239,480 K
  • 60-Month Beta 0.44
  • Price/Sales 40.99
  • Price/Cash Flow N/A
  • Price/Book 3.66
Trade RXRX with:

Options Overview Details

View History
  • Implied Volatility 83.27% ( -2.11%)
  • Historical Volatility 92.43%
  • IV Percentile 24%
  • IV Rank 34.98%
  • IV High 160.69% on 07/12/23
  • IV Low 41.61% on 03/30/23
  • Put/Call Vol Ratio 0.44
  • Today's Volume 764
  • Volume Avg (30-Day) 1,764
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 41,066
  • Open Int (30-Day) 35,818

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.45
  • Number of Estimates 5
  • High Estimate -0.30
  • Low Estimate -0.53
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -45.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.03 +50.94%
on 11/10/23
8.06 -5.71%
on 12/06/23
+1.97 (+34.99%)
since 11/08/23
3-Month
4.97 +52.92%
on 11/01/23
8.90 -14.56%
on 09/14/23
-0.46 (-5.71%)
since 09/08/23
52-Week
4.54 +67.40%
on 05/02/23
16.75 -54.61%
on 07/19/23
-1.74 (-18.63%)
since 12/08/22

Most Recent Stories

More News
1 Cathie Wood Stock With Over 100% Upside, According to Analysts

This biotech stock under $10 is the newest addition to Cathie Wood's flagship ARKK fund - and Wall Street analysts have high hopes for the shares, too.

NVDA : 475.06 (+1.95%)
TSLA : 243.84 (+0.49%)
U : 32.70 (+2.51%)
NVTA : 0.5724 (-0.26%)
ARKK : 49.18 (+1.84%)
$NASX : 14,403.97 (+0.45%)
RXRX : 7.60 (+0.80%)
Recursion Pharmaceuticals Wants to 4X Its Supercomputing Power for AI With the Help of Nvidia. Here's Why It Matters.

Scaling up means having more power to bring to bear on core activities.

NVDA : 475.06 (+1.95%)
RXRX : 7.60 (+0.80%)
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The popular growth investor keeps adding to some of her favorite stocks.

ZM : 73.06 (+1.57%)
TDOC : 19.21 (+0.05%)
RXRX : 7.60 (+0.80%)
This Stock Could Soar by 120%, According to Wall Street

Don't rush to buy shares just yet.

RXRX : 7.60 (+0.80%)
Cathie Wood Just Made a Big Bet on Recursion Pharmaceuticals Stock. Will It Pay Off?

Cathie Wood just gave the company a huge vote of confidence.

RXRX : 7.60 (+0.80%)
Unlocking AI investment opportunities in healthcare

AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.

INTC : 42.70 (+1.30%)
NVDA : 475.06 (+1.95%)
RXRX : 7.60 (+0.80%)
RLAY : 9.37 (+0.54%)
EXAI : 5.58 (-4.12%)
RENB : 3.49 (+3.87%)
BTAI : 3.17 (-9.43%)
2 Reasons to Buy Recursion Pharmaceuticals, and 1 Reason to Sell

Pioneering businesses tend to carry big risks, but also the potential for big rewards.

RXRX : 7.60 (+0.80%)
2 Risky Stocks With Massive Potential

Neither is doing well this year.

RXRX : 7.60 (+0.80%)
MDGL : 208.32 (-11.58%)
1 Artificial Intelligence Stock to Buy Hand Over Fist in October and 1 to Avoid

One of these players could win in AI -- and in the healthcare market, in general.

MRNA : 80.32 (+0.46%)
RXRX : 7.60 (+0.80%)
Is Recursion Pharmaceuticals Stock a Buy Now?

The company has grabbed plenty of headlines recently.

NVDA : 475.06 (+1.95%)
RXRX : 7.60 (+0.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY.

See More

Key Turning Points

3rd Resistance Point 8.17
2nd Resistance Point 7.93
1st Resistance Point 7.76
Last Price 7.60
1st Support Level 7.35
2nd Support Level 7.11
3rd Support Level 6.94

See More

52-Week High 16.75
Fibonacci 61.8% 12.08
Fibonacci 50% 10.64
Fibonacci 38.2% 9.20
Last Price 7.60
52-Week Low 4.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar